Baxter-JW-HK Inno.N-Kabi introduce 4th gen 3 chamber TPNs

Set to reorganize the KRW 150 bil 3rd gen TPN market next year

New lipid formulation parenteral nutrition introduced…fish-oil vs olive oil

Baxter, JW Pharmaceutical receives reimbursement for its Olimer N12 E Inj and Winuf A Plus Inj

Fresenius Kabi, HK Inno. N received approval… products receiving pricing calculations

The race to expand the market share of ‘new lipid formulation total parenteral nutrition’ has been ignited by pharmaceutical companies specializing in parenteral nutrition.

 

The new intravenous lipid total parenteral nutritions that have been introduced to the market are regarded as 4th generation total parenteral nutritions and are an amino acid admixture to the existing three-chamber bags for parenteral nutrition.

 

It consists of refined fish oil (Omega-3) or refined olive oil, amino acids, and glucose.

 

Baxter was the first company to enter the market with a 4th generation product, which received authorization in August last year.

 

Baxter’s Olimer N12E Inj is an olive oil containing amino acid-reinforced lipid emulsions that comes in650·1000·1500·2000ml sizes and are priced at KRW 29,746, KRW 37,777, KRW 43,835, and KRW 55,202, each.

 

The company launched the product in Korea after signing a domestic distribution agreement with Boryung Phramacetucial, a sales and marketing powerhouse in general hospitals in Korea.

 

Among domestic pharmaceutical companies, JW Pharmaceuticals, the domestic leader in the third-generation three-chamber bag for parenteral nutrition, was the first to receive approval and reimbursement for its new product and was expected to rival Baxter's Olimer N12E Inj.

 

In the case of the Winuf A Plus Inj has increased the ratio of amino acids by including refined fish oil, refined olive oil, and refined soybean oil, the fluid is being considered as an upgrade of the company's preexisting three-chamber bag Winurf Inj, which has a market size of KRW 70 billion.

 

Winuf A Plus Inj comes in 1089·1090·1438·1452ml sizes and are priced at KRW 41,609, KRW 41,197, KRW 46,049, and KRW 46,679, respectively.

 

HK Inno.

 

N’s Omapone Plus Inj, which uses refined fish oil, has also recently obtained approval from the Ministry of Food and Drug Safety and is receiving drug price calculations.

 

Although HK Inno.N failed to become the first domestic company to launch a 4th generation product, as its product comes after JW Pharmaceutical, HK Inno.N has newly registered a patent for a 'pharmaceutical composition comprising of omega fatty acids and fluid preparation that contains the same' to differentiate its product theoretically from others.

 

JW Pharmaceutical

Fresenius Kabi also received approval to import its Ntense Inj.

 

in September last year, which contains a higher proportion of amino acids such as refined fish oil.

 

The company plans to promote it as a next-generation product to replace its own Smofkabiven Inj.

 

In terms of the drug distribution performance, Smofkabiven Peripheral Inj posted KRW 27.1 billion in sales last year and ranked second in the third-generation three-chamber bag for parenteral nutrition following Winuf.

 

The price of Smofkabiven had suffered cuts due to the combination of products that contain the same components, but the company is looking to turn things around by introducing Ntense Inj.

 

According to reports, Ntense Inj and Omapone Plus are expected to receive prices that are similar to those set for Winuf A Plus.

 

Therefore, the industry prospect is that the fourth-generation lipid emulsions based on refined fish oil and olive oil will form a new market and ignite fierce competition in 2024.